Management Board

Shervin J. Korangy was appointed Chief Executive Officer effective October 12, 2026. He brings extensive international leadership experience in healthcare, life sciences and financial services. Most recently, he served as President and Chief Executive Officer of BVI Medical (BVI), where he spent nearly a decade (2017–2026) transforming the company into an ophthalmology-focused MedTech platform with products reaching almost 90 countries. Under his leadership, BVI built a robust pipeline of innovation, expanded its footprint into numerous new markets, and enhanced its portfolio across several new strategic product categories. He stepped down from BVI in January of 2026 and subsequently served as a senior advisor to BVI and TPG Capital.

Prior to BVI, Korangy was a senior executive with Swiss headquartered Novartis Group AG, one of the largest global healthcare companies, holding roles which included several country/regional commercial roles spanning medical devices, consumer healthcare, and pharmaceuticals as well as Global Head of Corporate Finance. He started his career and spent over 14 years with Blackstone, one of the world’s leading alternative investment firms, most recently as a Managing Director with experience spanning both the Restructuring/Special Situations and Private Equity businesses. In addition, he is a co-founder of Sight Sciences, a growth-stage medical device company focused on transforming glaucoma and dry eye treatment.

Korangy served as a member of the Supervisory Board of Fresenius Medical Care AG from 2023 until October 7, 2026. He has also served on several public and privately held corporate boards over the years including BVI Medical Ltd, Hain Celestial, Motus GI, Pelican Rouge Group, Pinnacle Foods Group, amongst others. He has served on The Wharton School’s Undergraduate Board since 2024 and previously served on The Wharton School’s McNulty Leadership Advisory Board, at the University of Pennsylvania.

He holds a Bachelor of Science in Economics with concentrations in Management and Finance from the Wharton School of the University of Pennsylvania.

CV¹

Dr. Jörg Häring was appointed Member of the Management Board responsible for Legal, Compliance and Human Resources and Labor Relations Director as of June 1, 2024. Prior to joining Fresenius Medical Care, Dr. Jörg Häring was a member of the Management Committee, Chief Legal & Assurance Officer and Secretary of the Board at the Spanish energy company Compañía Española de Petróleos (CEPSA), overseeing Legal, Corporate Audit, Risk Management, and Compliance globally. He previously spent 18 years with the Siemens Group, including nearly 13 years as General Counsel. Before joining Siemens, he worked at the law firm Cleary, Gottlieb, Steen & Hamilton in Frankfurt, Germany and Brussels, Belgium. Jörg Häring holds a PhD in law and a degree in economics from the University of Tübingen, Germany.

CV¹

Cassie McLean was appointed Chief Executive Officer of Care Delivery and member of the Management Board as of August 1, 2026. She joined Fresenius Medical Care in 2025 as President, Fresenius Kidney Care in the United States. Prior to joining Fresenius Medical Care, Cassie McLean served in leadership roles across mental health, kidney care, and integrated healthcare delivery systems. Most recently, she was Chief Executive Officer of Monte Nido, a leading provider of eating disorder treatment and recovery services. Previously, she was the Group Vice President of Operations and Admissions at DaVita Kidney Care, where she also held numerous operational, management and leadership roles during her 16 years with the company. Cassie McLean holds a Master of Public Administration in Healthcare Finance degree from New York University in the U.S. 

CV¹